Understanding Your GLP-1 Lab Results
Your results are in — and we're here to help you make sense of them. This guide walks you through every marker on your Biomeme Labs report, in plain language, so you know exactly what's going on with your body while on Ozempic, Wegovy, Mounjaro, or Zepbound.
How to Read Your Report
Your Biomeme Labs report focuses on mRNA gene expression — the real-time molecular data that standard blood work can't provide. Below, we also explain common standard lab markers for context, so you can see how traditional results compare with what Biomeme Labs reveals.
Reference: Standard Lab Markers
The markers your doctor typically orders — glucose, cholesterol, liver enzymes, thyroid, and inflammation. These are the traditional "vital signs" of metabolic health. Understanding what they show (and what they miss) helps you appreciate what mRNA monitoring adds.
- • Lagging indicators — reflect changes from weeks ago
- • Can't detect early cellular shifts or active resolution signaling
- • Important context for understanding what mRNA monitoring adds
Your Biomeme Labs Report: mRNA Gene Expression
The next-generation part — this section shows which genes your body is actively reading right now. Think of it as a real-time snapshot of what your cells are doing, not just what's floating in your blood.
- • Results organized across 3 Health Domains: Activation, Antiviral Response, and Resolution
- • Independent 0–100 percentile rankings calibrated to a healthy reference cohort
- • Longitudinal trajectory tracking: Settling / Resolving, Stable, or Rising / Primed across nodes
Remember: A single result outside the normal range doesn't mean something is wrong. Lab values need context — your medication, timing, hydration, and individual baseline all matter. When in doubt, share your report with your prescriber. That's what it's for.
Understanding Standard Lab Results
Your doctor may also order traditional lab panels as part of your GLP-1 care. Here's what each marker measures, what the ranges mean, and what to look for — so you can see what standard tests reveal versus what mRNA monitoring from Biomeme Labs adds.
Fasting Glucose & HbA1c
Glucose: 70–99 mg/dL · HbA1c: <5.7%
What it measures: Fasting glucose is your blood sugar after an overnight fast — a snapshot of right now. HbA1c is the bigger picture: your average blood sugar over the past 2–3 months.
If it's HIGH: If your glucose or A1c is still elevated, it doesn't necessarily mean your medication isn't working. It takes time. GLP-1 medications lower blood sugar gradually — many individuals see A1c improve by the 12-week mark. If levels remain high after 3+ months, your prescriber may adjust your dose.
If it's LOW: Mildly low glucose (60s) can happen, especially early in therapy or if you're eating very little. Symptoms include shakiness, sweating, or feeling lightheaded. If you're on insulin or a sulfonylurea alongside your GLP-1, low blood sugar is more of a concern — contact your provider.
When to talk to your doctor: Glucose consistently below 60 mg/dL, or A1c that hasn't budged after 12 weeks on a stable dose.
Fasting Insulin
Normal: 2.6–24.9 µIU/mL
What it measures: How much insulin your body is pumping out on an empty stomach. High levels mean your body is working overtime to manage blood sugar — a sign of insulin resistance.
If it's HIGH: Your body is still insulin-resistant. GLP-1 medications work to improve this over time. Many individuals see insulin levels start dropping within 8–12 weeks. If yours is still elevated, it may take more time — or your provider might combine strategies.
If it's LOW: Great news, usually. Falling insulin means your body is becoming more efficient. Exceptionally low levels are rare on GLP-1 therapy unless you're also on insulin or have another condition.
When to talk to your doctor: Insulin levels that haven't improved after 12 weeks, or levels that have dropped below 2 µIU/mL with symptoms.
Liver Enzymes: ALT & AST
ALT: 7–56 U/L · AST: 10–40 U/L
What they measure: ALT and AST are enzymes your liver releases when it's under stress or its cells are being damaged. Together, they're your liver's "check engine" light.
If they're HIGH: A temporary bump in liver enzymes is actually common during the first few months on GLP-1 therapy — especially during rapid weight loss. As your body breaks down stored fat, your liver works harder. GLP-1s generally improve fatty liver over time, but the transition can cause transient spikes. If levels are more than 3x the upper limit, your provider will want to investigate.
If they're LOW: Low liver enzymes are normal and not a concern. They just mean your liver isn't under stress.
When to talk to your doctor: ALT or AST levels above 3x normal (roughly >170 U/L for ALT or >120 U/L for AST), or if you're experiencing fatigue, abdominal pain, or yellowing skin.
Lipid Panel: LDL, HDL & Triglycerides
LDL: <100 mg/dL · HDL: >40 mg/dL · Triglycerides: <150 mg/dL
What they measure: Your cholesterol and fat levels — the numbers most associated with heart health. LDL is "bad" cholesterol, HDL is "good" cholesterol, and triglycerides are fat circulating in your blood.
If LDL is HIGH: It may take 8–12 weeks for GLP-1 therapy to noticeably improve LDL. If it's still elevated at 12+ weeks, diet, exercise, and possibly statin therapy may need to be discussed with your provider.
If triglycerides are HIGH: Triglycerides are usually the first lipid to respond to GLP-1 medications — often dropping within 4–8 weeks. If yours haven't budged, your diet (especially refined carbs and alcohol) may be a factor worth discussing.
If HDL is LOW: Low HDL is common in people with metabolic syndrome. It typically improves with sustained weight loss and exercise. GLP-1 therapy alone has a modest effect on HDL.
When to talk to your doctor: LDL above 160 mg/dL, triglycerides above 500 mg/dL, or HDL consistently below 35 mg/dL.
TSH (Thyroid-Stimulating Hormone)
Normal: 0.4–4.0 mIU/L
What it measures: TSH tells you how hard your thyroid gland is working. Your thyroid controls metabolism, energy, and body temperature — it's a critical safety marker during GLP-1 therapy.
If it's HIGH: High TSH suggests your thyroid may be underactive (hypothyroidism). This can cause fatigue, weight gain, and cold sensitivity — symptoms that overlap with GLP-1 side effects. Your provider will want to distinguish between the two.
If it's LOW: Low TSH may indicate an overactive thyroid (hyperthyroidism). GLP-1 medications carry an FDA boxed warning about medullary thyroid carcinoma risk (observed in animal studies). While human risk remains low, monitoring TSH is standard clinical practice.
When to talk to your doctor: Any TSH result outside the 0.4–4.0 range, especially if you have a personal or family history of thyroid disease or thyroid cancer.
hs-CRP (High-Sensitivity C-Reactive Protein)
Low risk: <1.0 mg/L · Average: 1.0–3.0 mg/L · High risk: >3.0 mg/L
What it measures: hs-CRP measures systemic inflammation — the kind of chronic, low-grade inflammation linked to heart disease, diabetes, and metabolic syndrome. It's not about a cold or infection; it's about the background fire your body may be running.
If it's HIGH: Persistent inflammation despite weight loss and GLP-1 therapy may signal that other factors (stress, sleep, diet, underlying conditions) are contributing. A single high reading can also be caused by a recent illness or injury — context matters.
If it's DROPPING: Great sign. GLP-1 medications have anti-inflammatory properties. A falling hs-CRP indicates decreased hepatic acute-phase protein synthesis beyond just weight loss. This is one of the most reassuring trends to see in your results.
When to talk to your doctor: hs-CRP consistently above 3.0 mg/L across multiple tests, or a sudden spike that can't be explained by illness.
CBC Highlights (Complete Blood Count)
WBC: 4,500–11,000 /µL · Hemoglobin: 12–17.5 g/dL · Platelets: 150,000–400,000 /µL
What it measures: A complete picture of your blood cells — white blood cells (immune system), red blood cells and hemoglobin (oxygen carrying), and platelets (clotting). It's a general health screener.
If anything is flagged: GLP-1 medications don't typically affect CBC values directly, so changes here are usually unrelated to your therapy. However, severe nausea or reduced eating can occasionally lead to mild anemia (low hemoglobin) or dehydration effects. Your provider can easily sort out what's going on.
When to talk to your doctor: Hemoglobin below 10 g/dL, WBC significantly above or below range, or if you're experiencing persistent fatigue, bruising, or unexplained infections.
Your mRNA Gene Expression Results
This is the core molecular intelligence that goes beyond standard blood work. Biomeme Labs measures the active gene expression of circulating immune cells across the 3 Health Domains — Activation, Antiviral Response, and Resolution — alongside Cellular Deconvolution. We deliberately report independent pathway signals rather than a single collapsed composite score, pairing neutral 0–100 percentile rankings with longitudinal trajectory tracking so you and your clinician can evaluate biological shifts in context without oversimplified good/bad labels.
Domain Percentile Ranking (0–100)
Each domain is scored independently against an unperturbed healthy reference cohort. Activation is an adaptive biological program, not inherently adverse or “bad” — scoring reflects the magnitude of pathway engagement rather than a moralized health grade.
Longitudinal Trajectory Tracking Across Nodes
Settling / Resolving
Calming activation tone or actively engaged resolution machinery indicating cellular stand-down.
Stable
Steady pathway expression across nodes; reflects established baseline or ongoing therapeutic equilibrium.
Rising / Primed
Heightened pathway engagement or immune readiness; interpreted in context of titration, challenge, or adaptation.
Activation Domain
Innate Sensing · IL-1 Cascades · Neutrophils & Monocytes · Platelet Containment
Circulating monocytes, neutrophils, and innate sensing pathways drive vascular and metabolic inflammation. In obesity and metabolic syndrome, these programs are primed into a chronic alarm state. This domain spans 7 pathways to track whether GLP-1 therapy is calming these frontline inflammatory effectors.
Settling / Quiescent Trajectory: Innate sensing, myeloid effector signaling, and platelet containment programs are actively calming. Vascular and tissue inflammatory stress is low.
Stable / Transitional State: Intermediate pathway engagement observed. Common during early dosage titration (weeks 4–8) as metabolic remodeling begins.
Rising / Primed Engagement: Elevated innate sensing or myeloid priming reflects active physiological defense programming or ongoing metabolic challenge, providing objective context for clinician review during weight plateaus.
Antiviral Response Domain
Type I Interferon · Antiviral Modules (S1–S4) · Pathogen Defense
Measures baseline Type I interferon-stimulated gene (ISG) cascades across 4 modular tiers (S1–S4). This enables the Inflammation Compass™ to verify whether your immune system is maintaining stable viral defense or experiencing chronic sterile interferon activation, intercurrent infection, or non-specific interferon pathway elevation.
Homeostatic Baseline: Interferon-stimulated cascades remain at healthy basal levels, indicating an unperturbed, balanced immune defense.
Stable / Mild ISG Expression: Low-level antiviral surveillance. May reflect recent viral challenge, seasonal immune shifts, or transient cellular stress.
Rising / Primed Interferon: Sustained elevation of antiviral cascades without active infection distinguishes non-specific interferon pathway elevation from metabolic inflammation.
Resolution Domain
Active Stand-Down · Checkpoint Regulators · Tissue Clearance Machinery
Inflammation does not simply fade away; it must be actively turned off by specialized biological programs. This domain spans 2 pathways — active regulatory stand-down and tissue clearance — to confirm whether your immune system is executing the biological steps required to finish the inflammatory arc.
Active / Robust Resolution: Regulatory checkpoint brakes and tissue clearance programs are actively expressed, confirming that inflammation is standing down.
Developing Regulation: Braking feedback is emerging but not yet fully established. Retesting at subsequent nodes tracks progression toward homeostatic stability.
Suppressed Stand-Down: Lower expression of stand-down machinery reveals that inflammatory programs lack active counter-regulation, leaving lingering low-grade smoldering activity.
Cellular Deconvolution
The Census Plus the Orders · Leukocyte Fractions · Activation vs. Abundance
Whole-blood RNA sequencing contains signals from many cell types simultaneously. Through computational deconvolution, the Inflammation Compass™ mathematically separates shifts in cell abundance (the census) from changes in cellular activation states (the orders).
Balanced Leukocyte Demographics: Proportions of monocytes, neutrophils, and lymphocytes align with healthy reference distributions, with low baseline cell stress.
Dynamic Compositional Shift: Moderate shifts in myeloid or lymphoid fractions during active metabolic remodeling and weight loss.
Skewed or Hyper-Activated Pool: Significant skew toward immature or hyper-activated myeloid populations, clarifying whether high pathway expression stems from more cells or hyperactive cells.
How Your Results Map to the
Nine-Stage Inflammatory Arc
Inflammation is not a single static number — it is an active, 9-stage biological program. Understanding where your scores sit across this arc reveals whether your body is completing the healing cycle.
Chronic Inflammation is an Incomplete Arc
In obesity and metabolic stress, the body triggers Stages 1–5 (Detect, Alert, Mobilize, Contain, Eliminate), but fails to actively switch on Stages 6 & 7 (Stop and Clean). Resolution is not a passive fade-out — it is an energy-consuming, active program of macrophage repolarization, specialized pro-resolving mediators (SPMs), and efferocytosis. When resolution machinery is flat, the immune system stays locked in a chronic, low-grade inflammatory loop.
Activation Domain
Covers Detect (TLR2/4 sensing), Alert (NF-κB, IL-1, TNF-α, IL-6 transcription), Mobilize (MCP-1 recruitment), Contain (platelet isolation), and Eliminate (phagocyte oxidative bursts). Tracks the quieting of frontline inflammatory effectors.
Antiviral Response
Covers baseline Type I Interferon cascades (modules S1–S4). Distinguishes metabolic calming from intercurrent viral challenges, vaccinations, or non-specific interferon pathway elevation.
Resolution Domain
Covers Stop (regulatory checkpoint brakes and M2 macrophage transition) and Clean (non-phlogistic efferocytosis of apoptotic neutrophils). Confirms that active biological shutdown machinery is operating.
How to Interpret Your Results:
Three Real-World Scenarios
How members and their prescribers evaluate multi-domain transcriptomics across common clinical situations during GLP-1 therapy.
The Scale Stall with Hidden Calming
Situation: Week 8 weight plateau on the bathroom scale; member worries medication has stopped working.
Pattern: Activation drops from 78th → 32nd percentile while Resolution rises from 25th → 64th percentile.
Meaning: Downstream metabolic and vascular calming is actively progressing despite unchanged scale weight. Reassures member to stay the course.
Aggressive Deficit with Stress Rebound
Situation: Rapid scale loss (3–4 lbs/week) alongside heavy fatigue, brain fog, and muscle weakness.
Pattern: Activation rebounds from 30th → 68th percentile with cortisol stress-axis and neutrophil priming; Resolution flat.
Meaning: Flags catabolic stress from excessive caloric restriction or overtraining. Prompts review of protein intake, sleep, and recovery.
The Off-Ramp Taper Surveillance
Situation: Month 12+ dosage spacing or maintenance tapering after reaching target metabolic goals.
Pattern: Pre-taper baseline documents steady state; post-taper retest at 3–6 months checks resolution autonomy.
Meaning: Verifies whether anti-inflammatory equilibrium remains stable, guarding against silent rebound driven by adipose epigenetic memory.
What To Do Next
Now that you understand your results, here's what to do with them.
Results Look Good
Your results show favorable pathway engagement. Continue following your prescribed protocol, nutrition, and movement plan. Schedule your next panel according to the recommended testing schedule so you can track your progress over time.
Something Was Flagged
Don't panic. A flagged result means a value fell outside the reference range — it does not automatically mean something is wrong. Many temporary changes are normal during GLP-1 therapy. Share your report with your prescriber so they can assess the result in context with your full health picture.
Non-Responder Signals
If your mRNA results show minimal metabolic engagement after 8+ weeks, or your blood work hasn't moved at all, you may be experiencing a biological plateau or non-response. Discuss these findings with your prescriber to evaluate your complete clinical picture.
Read our non-responder guide →Lean Mass & Muscle Health
Whole-blood transcriptomics measures systemic inflammatory calming, not muscle tissue directly. If you are concerned about lean mass loss during rapid weight reduction (which can account for 25–40% of total loss), pair your Inflammation Compass™ with clinical body composition scans (DXA), ensure adequate daily protein intake (1.2–2.0 g/kg), and maintain progressive resistance training.
Learn about lean mass preservation →Continue Your Monitoring Journey
Frequently Asked Questions
How do I read my GLP-1 lab results?
Your Biomeme Labs report focuses on mRNA gene expression data across 3 Health Domains (Activation, Antiviral Response, and Resolution) alongside Cellular Deconvolution. Each result pairs independent 0–100 percentile rankings with longitudinal trajectory tracking (Settling / Resolving, Stable, Rising / Primed) to provide clear biological context during GLP-1 therapy. Our results guide also explains common standard lab markers your doctor may order separately, so you can see how traditional blood work compares with what whole-blood transcriptomic monitoring reveals.
What does my mRNA report mean?
Your mRNA report shows what your circulating immune cells are actively transcribing right now. Results are structured around 3 Health Domains (Activation: innate sensing, neutrophils, monocytes, and platelets; Antiviral Response: Type I interferon cascades; and Resolution: active regulatory stand-down and tissue clearance machinery) plus Cellular Deconvolution. Neutral 0–100 percentile rankings scored independently against a healthy reference cohort and longitudinal trajectory tracking (Settling / Resolving, Stable, Rising / Primed) make it easy to understand each pathway at a glance without collapsing data into an oversimplified composite score or reductive good/bad labels.
How do I interpret an elevated Activation score or shifting trajectory?
The Inflammation Compass™ does not output binary “normal vs. abnormal” diagnostic cutoffs. Results are reported on neutral 0–100 percentile scales calibrated against a healthy reference cohort, alongside longitudinal trajectories (Settling / Resolving, Stable, Rising / Primed). Activation is an adaptive biological program, not inherently adverse. If your Activation percentile is elevated or your trajectory is rising, it simply reflects heightened immune engagement. Share your report with your prescribing clinician to review these trends alongside your complete clinical and lifestyle picture.
How often should I retest on GLP-1 therapy?
Our testing is structured around a 4-node longitudinal schedule: Node 1 establishes your initial baseline profile (Day 0), Node 2 tracks early kinetics (Week 4), Node 3 evaluates metabolic adaptation and resolution (Week 12), and Node 4 tracks long-term maintenance and off-ramp/discontinuation surveillance (Month 12+). Visit our testing schedule page for the full breakdown.
Ready for Your
Next Panel?
Tracking your results over time is where the real insight happens. Order your follow-up panel to see how your markers are trending.